CB2R/FAAH modulator-3 is a small-molecule research compound that functions as a cannabinoid receptor 2 (CB2R) agonist and a fatty acid amide hydrolase (FAAH) inhibitor. Reported activity includes CB2R Ki = 20.1 nM, CB1R Ki = 67.6 nM, and FAAH IC50 = 3.4 μM. It is intended for preclinical studies of inflammatory signaling, neurodegeneration, cancer-related pathways, and infection-associated inflammatory responses.
- Dual activity as CB2R agonist and FAAH inhibitor.
- Reported high CB2R affinity (low nanomolar Ki).
- Lower affinity for CB1R supporting receptor selectivity.
- Applicable to studies of inflammation, neurodegeneration, and cancer biology.
- High chemical purity suitable for research use.
- Available in small-mass and solution formats for assay workflows.